Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Shares Outstanding (Weighted Average) (2020 - 2025)

Cytek Biosciences' Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $127.6 million for Q2 2025.

  • For Q2 2025, Shares Outstanding (Weighted Average) fell 2.9% year-over-year to $127.6 million; the TTM value through Jun 2025 reached $127.6 million, down 2.9%, while the annual FY2023 figure was $135.3 million, 0.57% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $127.6 million in Q2 2025 per CTKB's latest filing, down from $131.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $136.2 million in Q3 2023 to a low of $31.6 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $112.5 million, with a median of $132.7 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 324.31% in 2022, then fell 3.71% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $76.7 million in 2021, then skyrocketed by 75.28% to $134.5 million in 2022, then increased by 0.57% to $135.3 million in 2023, then decreased by 3.08% to $131.1 million in 2024, then decreased by 2.66% to $127.6 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Shares Outstanding (Weighted Average) are $127.6 million (Q2 2025), $131.1 million (Q3 2024), and $131.4 million (Q2 2024).